Endocrinology application of molecular imaging: current role of PET/CT.

Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE

Publication: 2014- : Berlin : Springer
Original Publication: Milano, Published for the Italian Society of Endocrinology by Editrice Kurtis.

Positron Emission Tomography Computed Tomography*/methods ; Molecular Imaging*/methods ; Molecular Imaging*/trends ; Endocrinology*/methods ; Endocrinology*/trends ; Endocrine System Diseases*/diagnostic imaging; Humans ; Radiopharmaceuticals

Background: In recent years, nuclear medicine imaging methods have proven to be of paramount importance in a wide variety of diseases, particularly in oncology, where they are crucial for assessing the extent of disease when conventional methods fall short. Moreover, nuclear imaging modalities are able to better characterize lesions using target agents related to specific pathways (e.g. glucose metabolism, cellular proliferation, amino acid transport, lipid metabolism, specific receptor ligands). The clinical presentation of endocrine diseases encompasses a broad spectrum of sign and symptoms. Moreover, endocrine tumors show varying degrees of aggressiveness from well differentiated and indolent to highly aggressive cancers, respectively.
Rationale: With the application of new medicinal radio-compounds and increasingly advanced tomographic imaging technology, the utility of Positron Emission Tomography/Computed Tomography (PET/CT) in the field of endocrine diseases is expanding.
Aim: This review aims to analyze and summarize the primary indications of PET/CT, providing a practical approach for clinicians. A comprehensive literature search on PubMed was conducted to provide an updated overview of the available evidence regarding the use of PET/CT in endocrinology. Within this review, we will discuss the applications of PET/CT, compare different radiopharmaceuticals and highlight the uptake mechanism, excluding neuroendocrine carcinomas from discussion.
Conclusions: PET/CT is a valuable tool in diagnosing and managing endocrine disorders due to its capacity to furnish both functional and anatomical information, facilitate early lesion detection, guide treatment decisions, and monitor treatment response. Its non-invasive nature and precision make it an integral component of modern endocrine healthcare. This review aims to provide physicians with a clear perspective on the role of PET/CT imaging, discussing its emerging opportunities and appropriateness of use in endocrinological diseases.
(© 2024. The Author(s).)

Eur J Nucl Med Mol Imaging. 2022 May;49(6):1970-1984. (PMID: 34981165)
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1205-1215. (PMID: 36495325)
Ann Nucl Med. 2023 May;37(5):255-270. (PMID: 36933117)
Clin Nucl Med. 2023 Jul 1;48(7):638-639. (PMID: 37083830)
Hormones (Athens). 2023 Mar;22(1):131-138. (PMID: 36477790)
Thyroid. 2023 Aug;33(8):974-982. (PMID: 37171126)
Eur J Radiol. 2010 Mar;73(3):481-93. (PMID: 20089377)
Endocrinol Diabetes Nutr (Engl Ed). 2023 Mar;70(3):171-178. (PMID: 37030900)
Dis Esophagus. 2023 Sep 1;36(9):. (PMID: 36722353)
Q J Nucl Med Mol Imaging. 2023 Jun;67(2):130-137. (PMID: 37232932)
Am J Case Rep. 2023 May 10;24:e938676. (PMID: 37160900)
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2435-2445. (PMID: 36948598)
J Surg Oncol. 2023 Oct;128(5):764-768. (PMID: 37403579)
Med J Armed Forces India. 2009 Oct;65(4):353-8. (PMID: 27408291)
Mol Imaging Biol. 2023 Aug;25(4):720-726. (PMID: 36881250)
Presse Med. 2022 Jun;51(2):104114. (PMID: 35131316)
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. (PMID: 31392371)
Sci Rep. 2022 Oct 19;12(1):17427. (PMID: 36261462)
Clin Endocrinol (Oxf). 2023 Sep;99(3):233-245. (PMID: 37272391)
Q J Nucl Med Mol Imaging. 2023 Jun;67(2):114-121. (PMID: 36748984)
Oncology. 2022;100(2):74-81. (PMID: 34788758)
Surgery. 2023 Jan;173(1):117-123. (PMID: 36229257)
Mol Imaging Biol. 2023 Jun;25(3):483-494. (PMID: 36253663)
Clin Nucl Med. 2023 May 1;48(5):e232-e234. (PMID: 36854289)
Endocrine. 2023 Aug;81(2):183-193. (PMID: 36877452)
Medicine (Baltimore). 2023 Feb 3;102(5):e32751. (PMID: 36749225)
Medicine (Baltimore). 2023 May 19;102(20):e33724. (PMID: 37335717)
EJNMMI Res. 2017 Oct 27;7(1):90. (PMID: 29080017)
J Am Coll Radiol. 2021 Nov;18(11S):S251-S267. (PMID: 34794587)
Anticancer Res. 2023 Jan;43(1):183-190. (PMID: 36585178)
J Clin Med. 2023 Apr 17;12(8):. (PMID: 37109254)
Nat Med. 2023 Jan;29(1):190-202. (PMID: 36646800)
World J Gastroenterol. 2023 Sep 14;29(34):5082-5090. (PMID: 37753367)
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1419-37. (PMID: 12961037)
Nutrients. 2022 Dec 30;15(1):. (PMID: 36615844)
PET Clin. 2023 Apr;18(2):233-242. (PMID: 36585340)
Nucl Med Commun. 2023 Jul 1;44(7):640-645. (PMID: 37114410)
Semin Nucl Med. 2023 Jul;53(4):539-554. (PMID: 36623974)
Clin Nucl Med. 2023 Jun 1;48(6):e307-e309. (PMID: 36754357)
Cancer Imaging. 2023 Sep 12;23(1):85. (PMID: 37700359)
Semin Nucl Med. 2023 Jul;53(4):530-538. (PMID: 36966020)
Front Endocrinol (Lausanne). 2022 Oct 11;13:982972. (PMID: 36303876)
World J Surg Oncol. 2023 Sep 26;21(1):305. (PMID: 37749562)
Abdom Imaging. 2012 Dec;37(6):1004-20. (PMID: 22422069)
Front Endocrinol (Lausanne). 2021 Oct 20;12:723394. (PMID: 34744999)
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. (PMID: 28547177)
Langenbecks Arch Surg. 2023 Apr 13;408(1):150. (PMID: 37055669)
Hell J Nucl Med. 2023 Jan-Apr;26(1):41-46. (PMID: 37115220)
Clin Nucl Med. 2019 Aug;44(8):e497-e498. (PMID: 31274634)
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1134-1145. (PMID: 36435928)
Theranostics. 2018 Jun 24;8(14):3918-3931. (PMID: 30083270)
Cancers (Basel). 2023 Aug 27;15(17):. (PMID: 37686566)
Cancers (Basel). 2021 Oct 15;13(20):. (PMID: 34680321)
Semin Nucl Med. 2023 Jul;53(4):481-489. (PMID: 36702731)
Medicine (Baltimore). 2023 Sep 1;102(35):e34622. (PMID: 37657020)
Endocr Pract. 2009 Jul-Aug;15(5):450-3. (PMID: 19632968)
J Nucl Med. 2020 Dec;61(Suppl 2):263S-272S. (PMID: 33293447)
Cancers (Basel). 2021 Apr 10;13(8):. (PMID: 33920195)
Clin Endocrinol (Oxf). 2017 May;86(5):645-651. (PMID: 28160320)
Cancers (Basel). 2022 Mar 01;14(5):. (PMID: 35267580)
Endocrinol Diabetes Nutr (Engl Ed). 2021 Aug-Sep;68(7):481-488. (PMID: 34863413)
Ir J Med Sci. 2023 Aug;192(4):1695-1702. (PMID: 36399322)
Front Horm Res. 2016;45:133-41. (PMID: 27002335)
Clin Endocrinol (Oxf). 2023 Sep;99(3):262-271. (PMID: 36593125)
World J Surg. 2023 May;47(5):1231-1237. (PMID: 36599952)
JAMA Netw Open. 2023 Feb 1;6(2):e2255609. (PMID: 36795418)
Nucl Med Commun. 2023 Dec 1;44(12):1114-1125. (PMID: 37769014)
Langenbecks Arch Surg. 2016 Nov;401(7):925-935. (PMID: 27086309)
Nuklearmedizin. 2008;47(3):132-8. (PMID: 18493694)
Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1977-95. (PMID: 22926712)
Q J Nucl Med Mol Imaging. 2023 Jun;67(2):96-113. (PMID: 36995286)
Clin Nucl Med. 2023 Aug 1;48(8):e387-e389. (PMID: 37256731)
Nucl Med Rev Cent East Eur. 2023;26(0):49-51. (PMID: 36856091)
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2801-2822. (PMID: 33839893)
Hell J Nucl Med. 2023 Jan-Apr;26(1):2-8. (PMID: 37031417)

Keywords: 2-[18F]FDG; 6-[18F]FDOPA; Endocrine tumors; PET/CT; [11C]Choline; [18F]F-choline; [C1-11C]Methionine

0 (Radiopharmaceuticals)

Date Created: 20240605 Date Completed: 20240912 Latest Revision: 20240915

20240915

PMC11393017

10.1007/s40618-024-02400-8

38837101